Abraxane, carboplatin pack one-two punch in two types of lung cancer

August 25, 2009
Volume 18, Issue 8

SAN FRANCISCO-Albumin-bound nab-paclitaxel (Abraxane) with carboplatin showed antitumor activity against squamous and nonsquamous NSCLC, according to research presented at the 2009 World Conference on Lung Cancer (abstracts PD3.4.1 and PD3.3.4).

SAN FRANCISCO-Albumin-bound nab-paclitaxel (Abraxane) with carboplatin showed antitumor activity against squamous and nonsquamous NSCLC, according to research presented at the 2009 World Conference on Lung Cancer (abstracts PD3.4.1 and PD3.3.4).

The ongoing study includes 1,050 patients from 111 global sites. Abraxane was administered in escalating doses in combination with carboplatin. Data showed that those who received 100 mg/m2 weekly had higher overall response rates and longer PFS compared with patients who were on a dosing regimen every three weeks and other weekly dosing regimens.

Based on these phase II findings, Abraxis Bioscience has initiated a phase III trial to study weekly Abraxane with carboplatin vs paclitaxel (Taxol) for the treatment of advanced NSCLC.